Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 160

1.

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group.

Lancet. 2019 Jun 15;393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2.

2.

Correction: Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017.

Iniesta C, Álvarez-Del Arco D, García-Sousa LM, Alejos B, Díaz A, Sanz N, Garrido J, Meulbroek M, Pujol F, Moreno S, Fuster-RuizdeApodaca MJ, Coll P, Antela A, Del Romero J, Ayerdi O, Riera M, Hernández J, Del Amo J.

PLoS One. 2019 Apr 29;14(4):e0216376. doi: 10.1371/journal.pone.0216376. eCollection 2019.

3.

Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study.

Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Knobel H, Palacios R, Antela A, Blanco JR, Fulladosa X; VACH.

Nefrologia. 2019 Sep - Oct;39(5):497-505. doi: 10.1016/j.nefro.2019.01.009. Epub 2019 Apr 24. English, Spanish.

4.

Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions.

Kostaki EG, Flampouris A, Karamitros T, Chueca N, Alvarez M, Casas P, Alejos B, Hatzakis A, Garcia F, Paraskevis D; CoRIS.

Front Microbiol. 2019 Mar 11;10:370. doi: 10.3389/fmicb.2019.00370. eCollection 2019.

5.

Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR Study.

Podzamczer D, Rozas N, Domingo P, Miralles C, den Eynde EV, Romero A, Deig E, Knobel H, Pasquau J, Antela A, Clotet B, Geijo P, de Castro ER, Casado MA, Muñoz A, Casado A, For The Pro-Str Study Group.

Curr HIV Res. 2018;16(6):425-435. doi: 10.2174/1570162X17666190212163518.

PMID:
30760189
6.

Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain.

Knobel H, Domingo P, Suarez-Lozano I, Gutierrez F, Estrada V, Palacios R, Antela A, Blanco JR, Fulladosa X, Refollo E; VACH Cohort.

Enferm Infecc Microbiol Clin. 2019 Jun - Jul;37(6):373-379. doi: 10.1016/j.eimc.2018.09.015. Epub 2018 Oct 30. English, Spanish.

PMID:
30389268
7.

Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017.

Iniesta C, Álvarez-Del Arco D, García-Sousa LM, Alejos B, Díaz A, Sanz N, Garrido J, Meulbroek M, Pujol F, Moreno S, Fuster-Ruiz de Apocada MJ, Coll P, Antela A, Del Romero J, Ayerdi O, Riera M, Hernández J, Del Amo J.

PLoS One. 2018 Oct 19;13(10):e0204738. doi: 10.1371/journal.pone.0204738. eCollection 2018. Erratum in: PLoS One. 2019 Apr 29;14(4):e0216376.

8.

Primary prevention.

Antela A, Azcoaga A, Sampedro E, Poveda T.

Enferm Infecc Microbiol Clin. 2018 Sep;36 Suppl 1:31-34. doi: 10.1016/S0213-005X(18)30244-1. English, Spanish.

PMID:
30115406
9.

Chronicity, ageing and multimorbidity.

Brañas F, Azcoaga A, García Ontiveros M, Antela A.

Enferm Infecc Microbiol Clin. 2018 Sep;36 Suppl 1:15-18. doi: 10.1016/S0213-005X(18)30241-6. English, Spanish.

PMID:
30115402
10.

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study.

Manzardo C, Londoño MC, Castells L, Testillano M, Luis Montero J, Peñafiel J, Subirana M, Moreno A, Aguilera V, Luisa González-Diéguez M, Calvo-Pulido J, Xiol X, Salcedo M, Cuervas-Mons V, Manuel Sousa J, Suarez F, Serrano T, Ignacio Herrero J, Jiménez M, Fernandez JR, Giménez C, Del Campo S, Esteban-Mur JI, Crespo G, Moreno A, de la Rosa G, Rimola A, Miro JM; FIPSE LT-HIV investigators.

Am J Transplant. 2018 Oct;18(10):2513-2522. doi: 10.1111/ajt.14996. Epub 2018 Aug 13. Erratum in: Am J Transplant. 2019 Feb;19(2):614.

11.

HIV pre-exposure prophylaxis (PrEP) in Spain: political and administrative situation.

García LM, Iniesta C, Garrido J, Fuster MJ, Pujol F, Meulbroek M, Poveda T, Riera M, Antela A, Moreno S, Dalmau D, Rivero A, García D, Espacio R, Del Amo J.

Enferm Infecc Microbiol Clin. 2018 Jun 14. pii: S0213-005X(18)30199-X. doi: 10.1016/j.eimc.2018.05.012. [Epub ahead of print] English, Spanish.

PMID:
29910148
12.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
13.

Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016.

Moreno S, Antela A, García F, Del Amo J, Boix V, Coll P, Fortuny C, Sirvent JLG, Gutiérrez F, Iribarren JA, Llibre JM, Quirós JCLB, Losa JE, Lozano A, Meulbroek M, Olalla J, Pujol F, Pulido F, Crespo Casal M, García JG, Aldeguer JL, Molina JAP, Podzamczer Palter D, Román AR; Grupo Redactor de GESIDA/SEIMC.

Enferm Infecc Microbiol Clin. 2017 Jun - Jul;35(6):377-383. doi: 10.1016/j.eimc.2016.11.016. Epub 2017 Feb 22. English, Spanish.

PMID:
28236498
14.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group.

J Antimicrob Chemother. 2017 Jan;72(1):246-253. Epub 2016 Sep 13.

PMID:
27629070
15.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group.

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. JAMA. 2016 Nov 15;316(19):2048.

PMID:
27404185
16.

Oxidative Stress Predicts All-Cause Mortality in HIV-Infected Patients.

Masiá M, Padilla S, Fernández M, Rodríguez C, Moreno A, Oteo JA, Antela A, Moreno S, Del Amo J, Gutiérrez F; CoRIS, Biobanco.

PLoS One. 2016 Apr 25;11(4):e0153456. doi: 10.1371/journal.pone.0153456. eCollection 2016.

17.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Review.

PMID:
27056581
18.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

PMID:
26976381
19.

The role of tenofovir alafenamide in future HIV management.

Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon P, Pourcher-Martinez V, Di Perri G.

HIV Med. 2016 May;17 Suppl 2:4-16. doi: 10.1111/hiv.12401. Review.

20.

Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013.

Sobrino-Vegas P, Moreno S, Rubio R, Viciana P, Bernardino JI, Blanco JR, Bernal E, Asensi V, Pulido F, del Amo J, Hernando V; Cohorte de la Red de Investigación en Sida, Spain.

J Infect. 2016 May;72(5):587-96. doi: 10.1016/j.jinf.2016.01.017. Epub 2016 Feb 24.

Supplemental Content

Loading ...
Support Center